BG104368A - Novel polymorphic forms of cipamfylline - Google Patents

Novel polymorphic forms of cipamfylline

Info

Publication number
BG104368A
BG104368A BG104368A BG10436800A BG104368A BG 104368 A BG104368 A BG 104368A BG 104368 A BG104368 A BG 104368A BG 10436800 A BG10436800 A BG 10436800A BG 104368 A BG104368 A BG 104368A
Authority
BG
Bulgaria
Prior art keywords
cipamfylline
polymorphic forms
novel polymorphic
forms
novel
Prior art date
Application number
BG104368A
Other languages
Bulgarian (bg)
English (en)
Inventor
Drake Eggleston
Ian R. Lynch
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of BG104368A publication Critical patent/BG104368A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG104368A 1997-10-23 2000-04-21 Novel polymorphic forms of cipamfylline BG104368A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6323897P 1997-10-23 1997-10-23
PCT/US1998/022451 WO1999020625A1 (fr) 1997-10-23 1998-10-23 Nouvelles formes polymorphes de cipamfylline

Publications (1)

Publication Number Publication Date
BG104368A true BG104368A (en) 2001-02-28

Family

ID=22047900

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104368A BG104368A (en) 1997-10-23 2000-04-21 Novel polymorphic forms of cipamfylline

Country Status (28)

Country Link
US (2) US6583283B1 (fr)
EP (1) EP1025103A4 (fr)
JP (1) JP2001520228A (fr)
KR (1) KR20010031246A (fr)
CN (1) CN1280579A (fr)
AP (1) AP2000001793A0 (fr)
AR (1) AR015190A1 (fr)
AU (1) AU751561B2 (fr)
BG (1) BG104368A (fr)
BR (1) BR9814099A (fr)
CA (1) CA2306980A1 (fr)
CO (1) CO4990930A1 (fr)
DZ (1) DZ2629A1 (fr)
EA (1) EA003445B1 (fr)
HU (1) HUP0100019A3 (fr)
ID (1) ID23885A (fr)
IL (1) IL135711A0 (fr)
MA (1) MA24682A1 (fr)
NO (1) NO20002012L (fr)
NZ (1) NZ504051A (fr)
PE (1) PE122599A1 (fr)
PL (1) PL340257A1 (fr)
SA (1) SA99191117A (fr)
SK (1) SK5642000A3 (fr)
TR (1) TR200001109T2 (fr)
UY (2) UY25220A1 (fr)
WO (1) WO1999020625A1 (fr)
ZA (1) ZA989622B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248231T3 (es) 2001-01-31 2006-03-16 Pfizer Products Inc. Derivados de eteres utiles como inhibidores de las isozimas pde4.
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EE200300360A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
CN1489588A (zh) 2001-01-31 2004-04-14 �Ʒ� 用作pde4同功酶抑制剂的噻唑基,噁唑基,吡咯基,和咪唑基羧酸酰胺衍生物
JP2005529933A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビター多形体
EP1742627A4 (fr) 2004-05-06 2009-08-26 Plexxikon Inc Inhibiteurs de pde4b et leurs utulisations
WO2006026754A2 (fr) 2004-09-03 2006-03-09 Plexxikon, Inc. Inhibiteurs de la phosphodiesterase 4b (pde4b)
EP2082741A1 (fr) * 2005-09-20 2009-07-29 Scinopharm Singapore Pte, Ltd. Nouvelle forme cristalline d'hydrochlorure d'irinotécane

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
US6583283B1 (en) 2003-06-24
AU1274499A (en) 1999-05-10
NZ504051A (en) 2003-02-28
KR20010031246A (ko) 2001-04-16
EP1025103A1 (fr) 2000-08-09
UY25380A1 (es) 1999-11-17
JP2001520228A (ja) 2001-10-30
HUP0100019A3 (en) 2003-01-28
US20020173648A1 (en) 2002-11-21
HUP0100019A2 (hu) 2002-01-28
ID23885A (id) 2000-05-25
AU751561B2 (en) 2002-08-22
AP2000001793A0 (en) 2000-06-30
UY25220A1 (es) 2001-08-27
PL340257A1 (en) 2001-01-29
AR015190A1 (es) 2001-04-18
SK5642000A3 (en) 2000-09-12
PE122599A1 (es) 2000-02-12
TR200001109T2 (tr) 2000-09-21
WO1999020625A1 (fr) 1999-04-29
BR9814099A (pt) 2000-10-10
CO4990930A1 (es) 2000-12-26
EP1025103A4 (fr) 2001-11-14
EA003445B1 (ru) 2003-06-26
MA24682A1 (fr) 1999-07-01
SA99191117A (ar) 2005-12-03
NO20002012D0 (no) 2000-04-17
IL135711A0 (en) 2001-05-20
CA2306980A1 (fr) 1999-04-29
ZA989622B (en) 1999-04-23
EA200000448A1 (ru) 2000-10-30
NO20002012L (no) 2000-04-17
DZ2629A1 (fr) 2003-03-08
CN1280579A (zh) 2001-01-17

Similar Documents

Publication Publication Date Title
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
NZ335992A (en) Substituted pyrimidinone and pyridone compounds and methods of use
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
CA2269815A1 (fr) Thienopyrimidines ayant une action inhibitrice phosphodiesterasique v
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
WO1998024782A3 (fr) Composes pyrimidines substitues et leur utilisation
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
AU7164987A (en) Treatment of sexual dysfunction with buspirone
WO2003041643A3 (fr) Composes de zearalanol inhibant hsp90 et leurs procedes de production et d'utilisation
AU2399892A (en) Treatment of anxiety disorders by nerve stimulation
NO20002702L (no) Tienopyrimidiner
IL129337A0 (en) Bicyclic aryl carboxamides and their therapeutic use
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
DE50211929D1 (en) Pyrimidinderivate
BG104368A (en) Novel polymorphic forms of cipamfylline
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
WO2001040465A3 (fr) Compositions et procedes de traitement de maladies d'ordre immunologique
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
WO1999015160A3 (fr) Utilisation de 2-aminotetralines 6,7-substituees pour la preparation de compositions pharmaceutiques pour le traitement de pathologies inflammatoires et/ou auto-immunes